3Volker Heinemann LFvW, Thomas Decker AK, Ursula Vehling- Kaiser SA, et al. Randomized comparison of FOLFIRI plus cetux- imab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS wild-type metastatic colorectal cancer:German AIO study KRK-0306 (FIRE-3) [J]. J Clin Oncol,2013,31 (Suppl) :ab- stract LBA3506.
4Jones SE, Savin MA, Holmes FA, et al. Phase III trim comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclo- phosphamide as adjuvant therapy for operable breast cancer[ J ]. J Clin Oncol,2006,24(34) :5381-5387.
5Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer:a report of the V325 Study Group [ J]. J Clin Oncol, 2006,24(31 ) :4991-4997.
6Martin M, Pienkowski T, Mackey J, et al. Adjuvant doeetaxel for node-positive breast cancer[ J ]. N Engl J Med, 2005,352 ( 22 ) : 2302 -2313.
